Gutiérrez-Román CI, Carrillo-Torres O, Rascón-Martínez DM

Language: Spanish
References: 14
Page: 264-267
PDF size: 230.13 Kb.

ABSTRACT

Nociplasticity represents a paradigmatic advancement in the understanding and management of pain, particularly chronic pain. This concept refers to the alteration of nociception that leads to an increased sensitivity to pain without clear evidence of specific tissue damage or known somatosensory nervous system dysfunction. It is distinguished from traditionally recognized nociceptive and neuropathic mechanisms, explaining chronic painful conditions that defy previous classifications. Its research focuses on the neuroplastic changes within the central nervous system (CNS) that result in an altered perception of pain, and the adoption of the term reflects an evolution in the understanding of pain, emphasizing the importance of neurobiological factors in the experience of chronic pain. As research progresses, findings must translate into improved clinical practices, offering hope to millions of people suffering from chronic pain without an identifiable physical cause. Nociplasticity not only represents a promising area of research but also serves as a reminder of the need for innovative and personalized therapeutic approaches in pain management. The purpose of this mini-review is to analyze, based on the literature, how the definition and inclusion of nociplastic pain into the pain classification were developed.

REFERENCES

1. Alcántara Montero A, Sánchez Carnerero CI, Goicoechea García C. Terapias emergentes en desarrollo clínico y nuevas aportaciones en dolor neuropático. Rev Esp Anestesiol Reanim. 2019;66:324-334.

2. https://www.iasp-pain.org/wp-content/uploads/2022/04/revised-definition-flysheet_R2-1-1-1.pdf

3. IASP Subcommittee on Taxonomy. Pain terms: a list with definitions and notes on usage. Recommended by the IASP Subcommittee on Taxonomy. Pain. 1979;6:249-252.

4. Moix J. Análisis de los factores psicológicos moduladores del dolor crónico benigno. Anu Psicol. 2005;36:37-60.

5. Kosek E, Cohen M, Baron R, Gebhart GF, Mico JA, Rice AS, et al. Do we need a third mechanistic descriptor for chronic pain states? Pain. 2016;157:1382-6.

6. Fitzcharles MA, Cohen SP, Clauw DJ, Littlejohn G, Usui C, Hauser W. Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet. 2021;397:2098-2110.

7. White B, Driver S, Warren AM. Resilience and indicators of adjustment during rehabilitation from a spinal cord injury. Rehabil Psychol. 2010;55:23-32.

8. Bello-Villanueva AM, Benítez-Lara M, Oviedo-Trespalacios O. Características del dolor, aspectos psicológicos, calidad de vida y estrategias de afrontamiento en pacientes con dolor de espalda crónico en una ciudad de Colombia. Rev Colomb Anestesiol. 2017;45:310-316.

9. Langley J, Brenner R. What is an injury? Inj Prev. 2004;10:69-71.

10. Salinas LJ. Mecanismos de daño inmunológico. Rev Med Clin Condes. 2012;23:458-463.

11. Jadue AN, González AI. Inmunopatogenia de las enfermedades autoinmunes. Rev Med Clin Las Condes. 2012;23(4):464-72.

12. Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the international classification of diseases (ICD-11). Pain. 2019;160:19-27.

13. Chen G, Zhang YQ, Qadri TJ, Serhan CN, Ji RR. Microglia in pain: detrimental and protective roles in pathogenesis and resolution of pain. Cell Press. 2018;100:1292-1311.

14. Freynhagen R, Parada HA, Calderon-Ospina CA, Chen J, Rakhmawati Emril D, Fernández-Villacorta FJ, et al. Current understanding of the mixed pain concept: a brief narrative review. Curr Med Res Opin. 2019;35:1011-1018.